Literature DB >> 18385667

Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains.

N Leung1, M A Gertz, S R Zeldenrust, S V Rajkumar, A Dispenzieri, F C Fervenza, S Kumar, M Q Lacy, J A Lust, P R Greipp, T E Witzig, S R Hayman, S J Russell, R A Kyle, J L Winters.   

Abstract

Cast nephropathy is the most common cause of renal disease in multiple myeloma, however, treatment with plasma exchange remains controversial even after 3 randomized controlled studies. We sought to determine the importance of diagnostic confirmation and goal directed therapy in the treatment of cast nephropathy in forty patients with confirmed multiple myeloma and renal failure who underwent plasma exchange. A positive renal response was defined as a decrease by half in the presenting serum creatinine and dialysis independence. No baseline differences were noted between eventual renal responders and non-responders. Three quarters of the patients with biopsy proven cast nephropathy resolved their renal disease when the free light chains present in the serum were reduced by half or more but there was no significant response when the reduction was less. The median time to a response was about 2 months. In patients without cast nephropathy, renal recovery occurred despite reductions in free light chain levels of the serum. No association was found between free light chains in the serum, urinary monoclonal proteins, overall proteinuria and cast nephropathy. We found that the relationship between renal recovery and free light chain reduction was present only in patients with biopsy proven cast nephropathy showing the importance of extracorporeal light chain removal in this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18385667     DOI: 10.1038/ki.2008.108

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  49 in total

1.  Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.

Authors:  Colin A Hutchison; Paul Cockwell; Stephanie Stringer; Arthur Bradwell; Mark Cook; Morie A Gertz; Angela Dispenzieri; Jeffrey L Winters; Shaji Kumar; S Vincent Rajkumar; Robert A Kyle; Nelson Leung
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

Review 2.  The pathogenesis and diagnosis of acute kidney injury in multiple myeloma.

Authors:  Colin A Hutchison; Vecihi Batuman; Judith Behrens; Frank Bridoux; Christophe Sirac; Angela Dispenzieri; Guillermo A Herrera; Helen Lachmann; Paul W Sanders
Journal:  Nat Rev Nephrol       Date:  2011-11-01       Impact factor: 28.314

Review 3.  Myeloma light chain cast nephropathy, a review.

Authors:  Insara Jaffer Sathick; Maria Eleni Drosou; Nelson Leung
Journal:  J Nephrol       Date:  2018-05-05       Impact factor: 3.902

Review 4.  Principles of separation: indications and therapeutic targets for plasma exchange.

Authors:  Mark E Williams; Rasheed A Balogun
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

5.  Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.

Authors:  Beth M Faiman; Patricia Mangan; Jacy Spong; Joseph D Tariman
Journal:  Clin J Oncol Nurs       Date:  2011-08       Impact factor: 1.027

Review 6.  Serum free light chain assessment in monoclonal gammopathy and kidney disease.

Authors:  Colin A Hutchison; Kolitha Basnayake; Paul Cockwell
Journal:  Nat Rev Nephrol       Date:  2009-09-29       Impact factor: 28.314

7.  Successful treatment of myeloma cast nephropathy using bortezomib-based chemotherapy plus selective plasma exchange.

Authors:  Mayuko Kawabe; Izumi Yamamoto; Ai Katsuma; Naomi Hayashi; Yo Komatsuzaki; Yasuyuki Nakada; Akihiro Shimizu; Yudo Tanno; Ichiro Ohkido; Nobuo Tsuboi; Kazuhito Suzuki; Takaki Shimada; Yoji Ogasawara; Katsuki Sugiyama; Keisuke Aiba; Takashi Yokoo
Journal:  CEN Case Rep       Date:  2016-08-11

Review 8.  Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney-What We Know and What the Future May Hold.

Authors:  Sandhya Manohar; Samih H Nasr; Nelson Leung
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 9.  Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.

Authors:  P Fabbrini; K Finkel; M Gallieni; G Capasso; M Cavo; A Santoro; S Pasquali
Journal:  J Nephrol       Date:  2016-10-18       Impact factor: 3.902

10.  State-of-the-Art Management of Complications of Myeloma and Its Treatment.

Authors:  Monique A Hartley-Brown; Daniel M Sullivan; Rachid Baz
Journal:  Adv Hematol       Date:  2010-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.